CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock

CGON·NASDAQ

$54.42

-0.85%
HealthcareBiotechnology

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

At a Glance

Live Snapshot
Market Cap$4.80B
EPS-2.0800
P/E Ratio-26.16
Earnings Date08/07/2026

cgon

Selling, General and Administrative Expenses

Last Annual Value

73.53M

3-Year CAGR

126%

5-Year CAGR

74%

10-Year CAGR

32%

CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock Competitors Analysis of Selling, General and Administrative Expenses

CGON · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
73.53M
95.1%73.8%N/A 
337.20M
8.3%21.7%13.2%
349.00M
4.1%9.7%18.3%
70.88M
42.3%N/AN/A
427.32M
57.8%75.9%N/A
65.38M
44.1%62.5%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
27.20M
69.0%59.9%59.0%
342.50M
19.5%18.0%N/A
CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock Fair Value Envelope

CGON · NASDAQ

Our analysis suggests that CGON has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $54.42, this represents a potential HIDDEN relative to our calculated worth for CG Oncology, Inc. Common stock.

Intrinsic Value
Current Price: $54.42